Gerard Soula

This inventor holds 61 USPTO granted patents and 18 published patent applications, plus 8 CIPO patents and 1 EPO patent, primarily in Insulin Formulations (CPC class 5686). Top assignees: Rhone-Poulenc Industries, Adocia, Flamel Technologies. Active years: 1976-2020.

USPTO Granted Patents = 61 (Patent Applications = 18)

% Patents Active = 85.2

CIPO Patents = 8 (Patent Applications = 9)

EPO Patents = 1

Average Co-Inventor Count = 2.0

ph-index = 13

Forward Citations = 708(Granted Patents)

Forward Citations (Not Self Cited) = 677(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

20 out of 521

Rhone-Poulenc Industries

Rhone-Poulenc Specialites Chimiques

Rhone-Poulenc Chimie De Base

patents

8. 2 out of 24

Rhone-Poulenc Specialties Chimiques

patents

9. 1 out of 59

Flamel Ireland Limited

patents

10. 1 out of 1

Flamel Technologies (Societe Anonyme)

Years Active: 1976-2020

Loading Chart...

Areas of Expertise:

Insulin Formulation

Modified Release

Microcapsules

Osteogenic Proteins

Polysaccharides

Polyamino Acids

Hydrophobic Amino Acids

Composite Gel Microparticles

Organosilicon Compounds

Polyoxaalkyl Aminoalcohols

Antiadhesive Coatings

Hydrogenated Silanes

61 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10583175 - Rapid-acting insulin formulation comprising a substituted anionic compound (2020-03-10),

2. RE47084 - Oral medicinal product with modified release of at least one active principle in multimicrocapsular form (2018-10-15),

3. 9089476 - Injectable solution at pH 7 comprising at least one basal insulin whose PI is between 5.8 and 8.5 (2015-07-28),

4. 8734850 - Oral medicinal product with modified release of at least one active principle in multimicrocapsular form (2014-05-27),

5. 8669227 - Fast-acting insulin formulation (2014-03-11),

6. 8629124 - Dextran functionalized by hydrophobic amino acids (2014-01-14),

7. 8546356 - Administration form of osteogenic protein complexes (2013-10-01),

8. 8426382 - Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative (2013-04-23),

9. 8389661 - Complexes between an amphiphilic polymer and an osteogenic protein belonging to the family of BMPs (2013-03-05),

10. 8367640 - Complex consisted of a polysaccharide and an HBP (2013-02-05),

11. 8241620 - Complex polymere amphiphile-PDGF (2012-08-14),

12. 8197850 - Medicine based on anti-hyperglycaemic microcapsules with prolonged release and method for preparing same (2012-06-12),

13. 6180141 - Composite gel microparticles as active principle carriers (2001-01-30),

14. 6022562 - Medicinal and/or nutritional microcapsules for oral administration (2000-02-08),

15. 5914098 - Aerosol composition for forming a hydrated membrane, and applications (1999-06-22),

Title: **Gerard Soula: A Pioneer in Pharmaceutical Innovations**

Introduction

Gerard Soula, based in Meyzieu, France, is a prominent inventor known for his significant contributions to the pharmaceutical field. With an impressive portfolio of 61 patents, Soula has dedicated his career to developing innovative solutions that enhance medical treatments, particularly in the realm of drug delivery systems.

Latest Patents

Among Soula's latest patents is a groundbreaking formulation for rapid-acting insulin. This innovation comprises a composition in aqueous solution that includes insulin and at least one substituted anionic compound, which consists of a discrete number of saccharide units. This formulation aims to improve the efficacy and speed of insulin delivery, a critical advancement for diabetes management.

Another notable patent involves an oral medicinal product with modified release characteristics. This invention focuses on creating an improved oral pharmaceutical form that allows for controlled release of active ingredients through both time and pH triggering mechanisms. This dual-trigger system is designed to enhance the therapeutic effectiveness of medicines, ensuring that patients receive the right dose at the right time, which can revolutionize oral medication.

Career Highlights

Gerard Soula has made significant strides in his professional career by working with reputable companies in the pharmaceutical sector. He has been associated with Rhône-Poulenc Industries and Flamel Technologies, where he has collaborated on various innovative projects that have pushed the boundaries of drug formulation and delivery.

Collaborations

Throughout his career, Gerard has collaborated with esteemed coworkers, including Olivier Soula and Remi Soula. Their teamwork has yielded a number of patents and innovations in the pharmaceutical industry, highlighting the importance of collaboration in advancing scientific research and technological developments.

Conclusion

Gerard Soula's contributions to the field of pharmaceuticals through his numerous patents have established him as a notable figure in innovation. His work not only demonstrates his expertise as an inventor but also exemplifies the potential for advancements that improve patient outcomes in medical treatments.